RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $269
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Biogen but lowers the price target from $292 to $269.
October 04, 2024 | 2:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital's analyst Brian Abrahams maintains an Outperform rating on Biogen, indicating confidence in the company's performance, but lowers the price target from $292 to $269, suggesting a more conservative outlook on its stock price.
The Outperform rating suggests continued confidence in Biogen's performance, which is positive. However, the lowered price target indicates a more cautious outlook, balancing the impact to neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100